Using digital tools to help people with HIV complete tuberculosis prevention therapy
Digital adherence technologies to facilitate completion of short-course tuberculosis preventive therapy among people living with HIV
This study is looking at how affordable digital tools can help people with HIV stick to their tuberculosis prevention treatment, making it easier for them to manage their health and reduce the risk of getting TB.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10899559 on NIH RePORTER |
What this research studies
This research investigates how low-cost digital adherence technologies can support people living with HIV in completing tuberculosis preventive therapy. The study aims to adapt these technologies to meet the specific needs of patients, ensuring they can effectively manage their treatment regimen. By utilizing a human-centered design approach, the research seeks to enhance the acceptability and implementation of these digital tools in real-world settings. The ultimate goal is to reduce tuberculosis incidence among this vulnerable population through improved treatment adherence.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are at risk of developing tuberculosis and are eligible for preventive therapy.
Not a fit: Patients who are not living with HIV or those who have already completed tuberculosis preventive therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly lower the rates of tuberculosis among people living with HIV, ultimately saving lives.
How similar studies have performed: Previous research has shown promise in using digital adherence technologies for improving treatment adherence in various health contexts, indicating potential success for this approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Berger, Christopher Allen — University of California, San Francisco
- Study coordinator: Berger, Christopher Allen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.